Celltrion Healthcare (Formerly Known As Celltrion)
1000 Marina Boulevard
About Celltrion Healthcare (Formerly Known As Celltrion)Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines.
CEO: Jung Jini
Please click here for clinical trial information.
Tweets by Celltrion
73 articles with Celltrion Healthcare (Formerly Known As Celltrion)
11/9/2020It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.
Celltrion Launches Human Clinical Trial of Potential COVID-19 Antiviral Antibody Treatment Following Positive Pre-Clinical Results
Celltrion Group announced the launch of its Phase I human clinical trial investigating a potential antiviral antibody treatment for patients with COVID-19.
Celltrion Healthcare Receives Positive CHMP Opinion for an Additional Five Indications for Remsima® SC Including for Use in Inflammatory Bowel Disease and Ankylosing Spondylitis
Celltrion Healthcare announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended expanding the existing marketing authorisation for the subcutaneous formulation of Remsima® in an additional five indications: for the treatment of patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.
Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time
Pre-clinical data for Celltrion’s antiviral antibody treatment candidate demonstrate a 100-fold reduction in viral load of SARS-CoV-2 (COVID-19), as well as improvement in lung lesions
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.
Celltrion Completes Neutralisation Test on Candidate Monoclonal Antibodies (mAbs) for COVID-19 Antiviral Antibody Treatment
Celltrion Group announced that the company has successfully selected the most potent antibody candidates to neutralise SARS-CoV-2, the virus causing COVID-19.
Celltrion Group announced its successful transition to the second phase of development for an antiviral treatment to fight the novel coronavirus pandemic, following the completion of the first phase of securing 300 different types of antibodies that bind to the antigen last month.
Celltrion Accelerates Development of COVID-19 Antiviral Treatment and Aims to Launch Rapid Self-testing Kit
Celltrion Group announced key milestones in its efforts to fight the 2019 novel coronavirus pandemic.
Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA® (trastuzumab-pkrb) for Injection
Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA ® (trastuzumab-pkrb) for Injection
Celltrion’s chairman Jung Jin Seo announced at last week’s JP Morgan Healthcare Conference the company’s strategy for the next decade.
FDA Approved TemixysTM, a two-drug single-tablet antiretroviral (ARV) for HIV Treatment, will be Celltrion’s first branded product to be commercialized in 4Q 2019 through its direct-customer partnerships
Celltrion Healthcare Receives CHMP Positive Opinion for Novel Subcutaneous Formulation of CT-P13 (biosimilar infliximab) for the Treatment of People With Rheumatoid Arthritis
Celltrion Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for CT-P13 SC for marketing authorisation in the European Union (EU) in people with rheumatoid arthritis (RA).
Celltrion and Nan Fung Group to establish Vcell Healthcare Limited to Develop and Commercialize Biosimilars in China
Celltrion and Nan Fung Group announced the establishment of Vcell Healthcare Limited, a Joint Venture company between both parties.
Leading South Korean biopharmaceutical modernizes trial operations to maintain inspection readiness and have a comprehensive view of study status
Celltrion Partners with the Canadian Biotech Company, iProgen Biotech to Develop a Series of Novel ADCs
The deal aims to co-develop up to 4 ADCs including a novel ADC (Antibody-drug conjugate) that targets breast cancers expressing low levels of HER2 using iProgen’s proprietary antibody drug delivery technology.
The U.S. Food and Drug Administration approved another biosimilar. On Friday, the regulatory agency approved Herzuma, a biosimilar to Genentech’s Herceptin developed by South Korea-based Celltrion, Inc. and Israel-based Teva Pharmaceuticals.
Celltrion Healthcare: Biosimilars Have the Potential to Deliver Dramatic Cost Savings for US and European Healthcare Systems
As the global leader in biosimilars, Celltrion Healthcare aims to positively shape future healthcare by improving patient access to biosimilars
In August, Pfizer filed with the U.S. Food and Drug Administration (FDA) accusing Amgen and Roche of using social media to mislead doctors and patients about biosimilars and their effectiveness.
Celltrion and Teva Announce FDA Oncologic Drugs Advisory Committee Recommends Approval of Celltrion BLA for CT-P10, a Proposed Rituximab Biosimilar
If approved, CT-P10, a proposed biosimilar to Rituxan® (rituximab), will be the first rituximab biosimilar to be approved in the United States.